# US 2024/0139332 A1 · Modified Clostridial Neurotoxins as Vaccine and Conjugate Vaccine Platforms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0139332 A1
- Document ID: US20240139332A1
- Status: Published application
- Kind: A1
- Application number: 17/959,272
- Filed: 2022-10-03
- Published: 2024-05-02
- Earliest claimed: 2017-12-15
- Assignees: The Medical College of Wisconsin, Inc.; Wisconsin Alumni Research Foundation
- Applicants: The Medical College of Wisconsin, Inc.; Wisconsin Alumni Research Foundation
- Inventors: Joseph T. Barbieri; Eric A. Johnson; Sabine Pellett; William H. Tepp; Amanda Przedpelski
- Web page: https://patentgrep.com/patent/US20240139332A1

## CPC

- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- C07K 14/33: from Clostridium (G)
- A61K 39/0015: {Combination vaccines based on measles-mumps-rubella}
- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 31/04: Antibacterial agents
- C12N 15/102: {Mutagenizing nucleic acids}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55544: {Bacterial toxins}
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.

## Claims

### Claim 1

A modified tetanus toxin polypeptide comprising a sequence having mutations R372A, Y375F, E234Q, R1226L, and W1289A, and further comprising a mutation at least at one position selected from D767A, and E769A, wherein each position is numbered relative to SEQ ID NO:1, the polypeptide having reduced toxicity and receptor binding compared with the toxicity and receptor binding of SEQ ID NO:1.

### Claim 2 (depends on 1)

The modified polypeptide of claim 1, further comprising a mutation K768A.

### Claim 3 (depends on 2)

The modified polypeptide of claim 2, wherein the mutations comprise R372A, Y375F, E234Q, R1226L, K768A, and W1289A, and D767A or E769A.

### Claim 4 (depends on 1)

The modified polypeptide of claim 1, wherein the modified polypeptide comprises SEQ ID NO:4.

### Claim 5 (depends on 2)

The modified polypeptide of claim 2, wherein the mutations comprise R372A, Y375F, E234Q, D767A, E769A, K768A, R1226L, and W1289A.

### Claim 6 (depends on 2)

The modified polypeptide of claim 2, wherein the modified polypeptide comprises SEQ ID NO:5.

### Claim 7 (depends on 1)

The modified polypeptide of claim 1, further comprising a mutation at position Y26, wherein the position is numbered relative to SEQ ID NO:1.

### Claim 8 (depends on 7)

The modified polypeptide of claim 7, wherein the mutation at position Y26 and comprises Y26A.

### Claim 9 (depends on 7)

The modified polypeptide of claim 7, wherein the modified polypeptide is encoded by SEQ ID NO:6.

### Claim 10 (depends on 1)

The modified polypeptide of claim 1, further comprising a covalently linked carbohydrate or peptide, whereby the polypeptide is a polypeptide-carbohydrate conjugate or a polypeptide-peptide conjugate.

### Claim 11 (depends on 1)

A composition comprising a modified polypeptide according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

A method of reducing the risk of a subject developing tetanus by inducing an immune response through administering to the subject a therapeutically effective amount of a modified polypeptide according to claim 1.

### Claim 13 (depends on 12)

The method of claim 12, wherein the polypeptide further comprises a mutation K768A.

### Claim 14 (depends on 13)

The method of claim 13, wherein the polypeptide further comprises a mutation Y26A.

### Claim 15 (depends on 1)

An adjuvant comprising the modified polypeptide of claim 1.

### Claim 16 (depends on 1)

A vaccine comprising the modified polypeptide of claim 1.

### Claim 17

A method of obtaining an engineered bacterial protein toxoid having increased potency as a vaccine, the method comprising:
a) selecting one or more amino acid positions in each domain of an amino acid sequence encoding a multi-domain bacterial protein toxin, wherein each position is selected to inactivate a protein function associated with each domain, wherein the domains comprise two or more of a catalytic domain, a translocation domain, a receptor binding domain, and a substrate binding domain;
b) substituting a native amino acid residue at each selected position with a non-native amino acid residue, whereby the substitution inactivates one or more protein functions associated with the domain; and
c) expressing in a host cell a nucleic acid sequence encoding a full-length bacterial protein toxin comprising the substituted non-native amino acid residues, whereby the expressed protein exhibits partial or complete loss of catalytic activity, receptor binding activity, translocation activity, or substrate binding activity relative to the full-length bacterial protein toxin comprising the native amino acids.

### Claim 18 (depends on 17)

The method of claim 17, wherein selecting comprises identifying individual functional amino acid residues based on primary sequence or structure of the bacterial protein toxin.

### Claim 19 (depends on 18)

The method of claim 18, wherein the structure is obtained using x-ray crystallography, electron microscopy, nuclear magnetic resonance spectroscopy, computational protein structure modeling, or a combination thereof.

### Claim 20 (depends on 17)

The method of claim 17, wherein selecting comprises identifying individual amino acid residues that can be modified without destabilizing the full-length protein or without loss of immunogenicity.
